Market Analysis From Decision Resources
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Multiple Sclerosis
You may also be interested in...
Betaseron Adds Secondary Progressive MS Use; Limited To Relapsing Patients
Berlex/Chiron’s Betaseron indication has been expanded to include secondary progressive multiple sclerosis, but approval is limited to the subset of patients who continue to have relapsing disease.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011